Caris Life Sciences, Inc. (CAI)
CAI moved a median of -0.27% 30 minutes after news, and -0.88% by the close. How CAI actually reacts to news — the realized, point-in-time move the market made, measured across 126 labeled events over the last three years with zero look-ahead.
CAI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.63% | 36% | 126 |
| 30-min | -0.27% | 48% | 126 |
| 60-min | -0.09% | 44% | 126 |
| to close | -0.88% | 41% | 124 |
| Middle 50% of CAI reactions | -1.21% to +0.81% |
|---|---|
| Median reaction (30-min) | -0.27% |
| Measured reactions | 126 |
Half of all Caris Life Sciences, Inc. news events land between -1.21% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CAI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 23 | +0.30% | 61% | +1.01% |
| Rating reiterations | 20 | -0.44% | 35% | -2.68% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CAI ranks against every other measured name →
That’s how CAI usually reacts — get an email when it moves on news →Email me when CAI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CAI's baseline. Nothing else.
Recent CAI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 | Press release | PR Newswire | +0.32% | +7.66% | |
| Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026 | Press release | PR Newswire | +2.09% | +3.51% | |
| Form 8-K Caris Life Sciences, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +3.29% | +10.46% | |
| Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect | Press release | PR Newswire | +1.25% | -0.84% | |
| Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer | Press release | PR Newswire | -1.03% | -1.31% | |
| Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer | Press release | PR Newswire | -0.15% | -1.64% | |
| Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Press release | PR Newswire | +1.21% | +5.26% | |
| Form 10-Q Caris Life Sciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.21% | +5.26% | |
| Form 8-K Caris Life Sciences, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | +5.26% | |
| Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | PR Newswire | -0.37% | -6.95% | |
| Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing | Press release | PR Newswire | -0.64% | -0.47% | |
| Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test | Press release | PR Newswire | +1.19% | +3.65% | |
| Caris Life Sciences Announces Dual Listing on NYSE Texas | Press release | PR Newswire | +0.33% | -1.21% | |
| Form 8-A12B Caris Life Sciences, | SEC filing · Form 8-A12B | SEC EDGAR | -0.17% | -1.26% | |
| Form CERT Caris Life Sciences, | SEC filing · Form CERT | SEC EDGAR | +0.17% | -1.15% | |
| Caris Life Sciences Announces Share Repurchase Program | Press release | PR Newswire | -1.35% | -7.56% | |
| Form 8-K Caris Life Sciences, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -7.56% | |
| Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing | Press release | PR Newswire | -1.21% | -1.21% | |
| Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | Press release | PR Newswire | +1.21% | -4.59% | |
| Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels | Press release | PR Newswire | +0.26% | -0.44% | |
| Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization | Press release | PR Newswire | -2.29% | -1.48% | |
| Form 10-Q Caris Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.29% | -1.48% | |
| Caris Life Sciences Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -0.59% | -3.87% | |
| Form 8-K Caris Life Sciences, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -3.87% | |
| Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis | Press release | PR Newswire | -0.82% | +0.53% | |
| Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies | Press release | PR Newswire | +2.18% | +1.91% | |
| Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients | Press release | PR Newswire | -0.82% | -2.58% | |
| Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | PR Newswire | -0.45% | +1.51% | |
| Form ARS Caris Life Sciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.79% | -2.99% | |
| Form DEF 14A Caris Life Sciences, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | -2.79% | -2.99% | |
| Form DEFA14A Caris Life Sciences, | SEC filing · Form DEFA14A | SEC EDGAR | -2.79% | -2.99% | |
| Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | PR Newswire | +0.20% | +1.43% | |
| Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center | Press release | PR Newswire | +1.21% | +0.71% | |
| Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients | Press release | PR Newswire | +0.10% | +2.80% | |
| Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients | Press release | PR Newswire | +1.21% | -1.31% | |
| Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies | Press release | PR Newswire | -2.31% | +3.65% | |
| Form 8-K Caris Life Sciences, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -0.57% | |
| Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect | Press release | PR Newswire | -0.08% | +1.32% | |
| Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer | Press release | PR Newswire | -0.38% | -0.27% | |
| Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 | Press release | PR Newswire | -0.89% | -5.31% | |
| Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month | Press release | PR Newswire | -0.03% | +1.96% | |
| Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer | Press release | PR Newswire | +1.53% | +4.38% | |
| Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting | Press release | PR Newswire | -1.19% | +0.43% | |
| Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer | Press release | PR Newswire | +0.49% | +3.83% | |
| Form 10-K Caris Life Sciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.28% | +1.27% | |
| Caris Life Sciences Completes Interim Readout of Achieve 1 Study | Press release | PR Newswire | -4.21% | -4.28% | |
| Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook | Press release | PR Newswire | -4.21% | -4.28% | |
| Form 8-K Caris Life Sciences, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -4.21% | -4.28% | |
| Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug | Press release | PR Newswire | -1.28% | +3.82% | |
| Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | PR Newswire | +1.11% | -8.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CAI section they belong to.
Where else CAI is measured.
CAI earnings → · Analyst actions → · SEC filings →
Other Industrials names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NRC Group Holdings Corp (NRCG) | 128 | 0.00% | 42% |
| Omega Flex, Inc. (OFLX) | 127 | +0.08% | 54% |
| SKF AB S/ADR (SKFRY) | 125 | 0.00% | 36% |
| Azul S.A. American Depositary Shares, each representing two (2) (AZUL) | 124 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Industrials names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Caris Life Sciences, Inc.'s median reaction calculated?
Every labeled CAI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 126 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CAI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CAI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.